SALUGGIA, Italy, HILDEN, Germany, and GERMANTOWN, Maryland, January 8, 2018 /PRNewswire/ --
- QIAGEN's QuantiFERON-TB customers to gain access to fully automated workflow solution
- DiaSorin to add novel content to already broad LIAISON menu, over 7,000 systems installed
- QIAGEN announces milestone of over 40 million QuantiFERON-TB tests since launch
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Stock Exchange: QIA) and DiaSorin (FTSE Italy Mid Cap: DIA) announced today a groundbreaking partnership that plans to add QIAGEN's QuantiFERON-TB diagnostic test to the menu of DiaSorin's LIAISON family of fully automated analyzers.
This addition will enable customers of both companies to process QuantiFERON-TB Gold Plus (QFT-Plus), the fourth-generation modern gold standard for latent tuberculosis (TB) detection, on LIAISON family platforms. Laboratories using QFT-Plus to safeguard at-risk patients by screening for latent TB infection will have access to a fully automated, flexible workflow on LIAISON family analyzers in addition to the currently available workflow solutions. More than 7,000 LIAISON systems have already placed worldwide, primarily in hospital laboratories.
QFT-Plus marks the first assay from QIAGEN's QuantiFERON portfolio that is planned to be adapted for use on the LIAISON family systems. Additional assays based on QuantiFERON technology, which offers a unique, efficient way to detect asymptomatic infections and other risks that cannot be discovered with standard diagnostic technologies, are under consideration.
QuantiFERON assays such as QFT-Plus are based on two components: (1) QuantiFERON Blood Collection Tubes, which contain key components of the test reaction that is uniquely performed in tube after blood collection; and (2) the QuantiFERON test read-out components, which are used to measure the release of interferon gamma after in-tube incubation. QFT-Plus currently runs in laboratories on standard detection equipment.
Click here for the full press release: https://corporate.qiagen.com/newsroom/press-releases/2017/20180108_DiaSorin_LIAISON_QFT?sc_lang=en
For additional information, please contact
Investor Relations & Corporate Communication Senior Director
Ines Di Terlizzi
Tel: +49 2103 29 11711
Tel: +49 2103 29 11826